Group 1 - Xencor (XNCR) has experienced significant selling pressure, resulting in a 23.7% decline over the past four weeks, but it is now considered oversold, indicating potential for recovery as analysts expect improved earnings [1] - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - The RSI helps investors identify potential price reversals, suggesting that if a stock is undervalued due to excessive selling, it may present a buying opportunity [3] Group 2 - The RSI for XNCR is currently at 20.84, suggesting that the heavy selling may be nearing exhaustion and a trend reversal could occur soon [5] - Analysts have raised earnings estimates for XNCR, with a 1.6% increase in the consensus EPS estimate over the last 30 days, indicating potential price appreciation [6] - XNCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the likelihood of a turnaround [7]

Core Viewpoint - Xencor (XNCR) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade for Xencor reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [4]. - Xencor is projected to earn -$3.68 per share for the fiscal year ending December 2024, representing a year-over-year decline of 76.9% [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, indicating superior earnings estimate revisions [8][9].

Financial Position - Xencor has a strong financial position with approximately $707 million in cash, cash equivalents, and marketable debt as of December 31, 2024[9]. Drug Development Pipeline - The company is advancing three novel T-cell engagers (TCEs) in Phase 1 studies focused on oncology, specifically targeting metastatic castration-resistant prostate cancer (mCRPC) and first-line non-small cell lung cancer (NSCLC)[7]. - XmAb942 (Xtend™ TL1A) is set to initiate studies in Q4 2024, while Plamotamab (CD20xCD3) is expected to enter Phase 1 in the first half of 2025[7]. - XmAb819 (ENPP3 x CD3) is currently in a Phase 1 dose escalation study for clear cell renal cell carcinoma (ccRCC), showing promising initial data with no maximum tolerated dose reached[21]. - XmAb541 (CLDN6 x CD3) is also in Phase 1, demonstrating high selectivity for CLDN6 over similar proteins, targeting ovarian and endometrial cancers[23]. - XmAb808 (B7-H3 x CD28) is in Phase 1, designed to enhance selective T cell activation in solid tumors, with ongoing patient enrollment[35]. - XmAb942 and XmAb TL1A x IL-23 are in development for ulcerative colitis, leveraging validated half-life extension technology[75]. - The first-in-human clinical study for XmAb942 is planned to initiate in Q4 2024[29]. - The initiation of Phase 1/2 study for Plamotamab (CD20 x CD3) in rheumatoid arthritis is set to begin[95]. - XmAb942 is expected to have single ascending dose (SAD) and multiple ascending dose (MAD) readouts in the immunology portfolio[95]. - XmAb717-04 and XmAb717-05 expansion readouts are anticipated in 1H 2025[93]. - The first-in-class potential for XmAb TL1A x IL-23 is being explored with a study planned for 2026[82]. Technology and Innovation - The company has a robust patent portfolio with over 1,600 patents issued and pending worldwide, enhancing its competitive edge in the market[7]. - Xencor's drug development strategy emphasizes rapid prototyping and strict evaluation of data to maximize outcomes for stakeholders[9]. - The company’s Xtend™ Fc technology has shown to significantly improve half-life and dosing frequency compared to traditional antibodies[77]. - XmAb942 utilizes Xtend™ Fc domain technology with a half-life of 23 days, supporting dosing every 8 to 12 weeks[29]. Collaborations and Market Strategy - The company is exploring technology licensing to expand its pipeline with minimal opportunity cost, indicating a strategic approach to market expansion[13]. - Xencor's collaborations with Johnson & Johnson focus on prostate cancer combinations, leveraging access to J&J's resources for enhanced development[34]. Market Opportunities - Current market for rheumatoid arthritis treatments exceeds $20 billion, with unmet needs for moderate-to-severe systemic lupus erythematosus (SLE) estimated at over $5 billion in the US[44]. - The global IBD drug market is projected to exceed $23 billion by 2030, highlighting significant unmet medical needs in inflammatory bowel disease[72]. - The bispecific antibody class is positioned to address significant limitations in current autoimmune disease treatments, with ongoing studies supporting its efficacy[43]. Clinical Outcomes - Vudalimab, a dual checkpoint inhibitor (PD-1 x CTLA-4), has shown a low rate of treatment discontinuation due to adverse events in ongoing studies[91]. - Vudalimab monotherapy has demonstrated clinical responses in 5 out of 12 evaluable patients with metastatic castration-resistant prostate cancer (mCRPC)[93]. - XmAb drug candidates are advancing with multiple dose expansions planned, including XmAb819 and XmAb808 in oncology[95]. - The company aims to evaluate the safety of Vudalimab in combination with chemotherapy for non-small cell lung cancer (NSCLC)[93]. - XmAb657, designed for autoimmune diseases, has demonstrated over 90% reduction in B-cell counts in both bone marrow and whole blood across dose cohorts[56]. - Plamotamab, a subcutaneous CD20 x CD3 bispecific antibody, is planned for Phase 1b/2a study initiation in the first half of 2025, focusing on rheumatoid arthritis[58].

Core Viewpoint - Xencor (XNCR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on changes in earnings estimates, leading to significant stock price movements [4]. Company Performance and Outlook - Xencor is projected to earn -$3.71 per share for the fiscal year ending December 2024, reflecting a year-over-year decline of 78.4% [8]. - Despite the negative earnings projection, analysts have raised their estimates for Xencor, with the Zacks Consensus Estimate increasing by 11.1% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating [9][10]. - Xencor's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].

Xencor (XNCR) closed the last trading session at $26.60, gaining 23.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35 indicates a 31.6% upside potential.The average comprises 11 short-term price targets ranging from a low of $22 to a high of $60, with a standard deviation of $9.77. While the lowest estimate indicates a decline of 17.3% from the current price level, the most op ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - Xencor (XNCR) shares have increased by 5.9% recently, with a mean price target of $35.42 suggesting a potential upside of 53.5% from the current price of $23.07 [1] Price Targets - The average price target consists of 12 estimates ranging from a low of $20 to a high of $60, with a standard deviation of $11.19, indicating variability among analysts [2] - The lowest estimate suggests a decline of 13.3%, while the highest indicates a potential upside of 160.1% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [7] Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [9] - Over the past 30 days, six earnings estimates for XNCR have been revised upward, leading to a 7.9% increase in the Zacks Consensus Estimate [10] - XNCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as they can often mislead investors [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term movin ...

Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.55%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.85 per share when it actually produced a loss of $1.07, delivering a surprise ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------|--------------------------- ...